About
About Nipro Corporation
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses worldwide. The company offers renal products; interventional products, such as cardiovascular products, endovascular products, and accessories; and hospital products, including hypodermic needles, syringes, IV sets and catheters, 3-way stopcocks, infusion sets, balloon infusers, etc. It also provides cardiopulmonary products comprising oxygenators, cardioplegia heat exchangers, perfusion tubing sets, arterial filters, hemoconcentrators, and venous and arterial cannulae; and enzymes, as well as contract development and manufacturing services. In addition, the company offers pharmaceutical combination products consisting of dual chamber bags, pre-filled syringes, and half-type kits; and integrated services, such as development, manufacturing, inspection, and packaging. Further, it provides glass containers, rubber stoppers, glass tubes, and other supplies for medical use; supplies for other industries; and drug administration systems, as well as autologous bone-marrow mesenchymal stem cells, culture products, and cell preservation products. The company was founded in 1947 and is headquartered in Settsu, Japan.
Research context
Nipro Corporation appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
Nipro Corporation is currently in a long term uptrend where the price is trading 5.1% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.5.
Nipro Corporation's total revenue rose by 4.2% to $119B since the same quarter in the previous year.
Its net income has dropped by 1.4% to $5B since the same quarter in the previous year.
Based on the above factors, Nipro Corporation gets an overall score of 3/5.